4 Drug/Biotech Stocks Making A Mark In RNAi Therapeutics

 | Apr 10, 2019 09:27PM ET

Biotech bigwig Regeneron Pharmaceuticals, Inc.’s (NASDAQ:REGN) recently extended collaboration agreement with Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) brought ribonucleic acid interference (RNAi) therapeutics in focus.

The companies will work together to discover, develop and commercialize RNAi therapeutics for a broad range of diseases by addressing disease targets expressed in the eye and central nervous system (CNS) in addition to a select number of targets expressed in the liver. Regeneron will make a $400-million upfront payment to Alnylam. It will also purchase $400 million of Alnylam equity at $90.00 per share. Additionally, Alnylam is eligible to receive up to an additional $200 million in milestone payments.

The collaboration with Alnylam will give Regeneron an option to have a pipeline based on RNAi technology.

In 2018, the FDA approved Alnylam’s Onpattro for the treatment of polyneuropathy of hATTR amyloidosis in adults in the United States and in adults with Stage 1 or Stage 2 polyneuropathy in the EU. This is the first FDA-approved treatment for patients with polyneuropathy caused by hATTR, a rare, and often fatal genetic disease. It is also the first FDA approval of a new class of drugs called small interfering RNA (siRNA) treatment.

What is RNAi?

RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. A revolutionary approach, RNAi therapeutics comprises siRNA and works by silencing messenger RNA, or mRNA, that encode for disease-causing proteins.

Consequently, a lot of companies are investing a sizeable chunk of their R&D budget to develop treatments using RNAi based technology.

4 Companies Developing Candidates Using RNAi Technology

Here we take a look at some other companies that have promising candidates:

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) develops therapies that trigger the RNA interference mechanism. The company has a broad portfolio of RNA chemistries. ARO-AAT, an RNAi therapeutic candidate for the treatment of liver disease associated with alpha-1 antitrypsin deficiency, is one of the key candidates. The company completed a phase I randomized, double-blind, placebo controlled single-ascending dose (SAD) and multiple-ascending dose (MAD) study to evaluate the safety, tolerability, pharmacokinetics, and effect of subcutaneous doses of ARO-AAT on serum alpha-1 antitrypsin levels in healthy adult volunteers in 2018 and plans to initiate a phase II study in 2019.

Other candidates include ARO-APOC3 for hypertriglyceridemia, ARO-ANG3 for dyslipidemia, ARO-ENaC for cystic fibrosis, and ARO-HIF2 for renal cell carcinoma. In 2016, the company out licensed ARO-LPA (AMG 890) for cardiovascular disease to Amgen Inc (NASDAQ:AMGN). The company also has a license and collaboration agreement with Amgen for ARO-AMG1 for an undisclosed genetically validated cardiovascular target. ARO-HBV for chronic hepatitis B virus was out-licensed to Janssen Pharmaceuticals, Inc. in October 2018.